drugset / Trial / NCT00752141

Cognitive Effects of Oral Oxybutynin and Oxybutynin Chloride Topical Gel in Older Volunteers

NCT00752141 ↗

Phase 1 Completed 153 enrolled Watson Pharmaceuticals
RandomizedParallel-groupTriple-blind

Summary

The purpose of this study is to explore the possible cognitive effects of oxybutynin tablets and oxybutynin gel.

Timeline

Start
2008-09
Primary completion
2008-10
Completion
—

Outcome

Missed primary endpoint

paper NFAT Delayed Recall tests revealed no significant treatment differences (overall, p = 0.2733; OTG vs placebo, p = 0.1551; OXB-IR vs placebo, p = 0.1767). PMID 22909146 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxybutynin Small molecule 5 mg Oral
Subject Oxybutynin Small molecule 100 mg Oral

Indications

No indication recorded.